论文部分内容阅读
胰岛素至今仍是治疗1型及2型糖尿病的基本药物。但由于胰岛素的给药途径主要依赖频繁注射,因此给患者带来诸多不便和痛苦。为解决这个问题相关学者已进行很多研究。随着胰岛素肺部吸入装置和剂型技术的发展,在临床研究中发现胰岛素经肺全身性用药可减少1型糖尿病所需的多次注射,并使2型糖尿病的胰岛素治疗更易接受。近年来胰岛素肺部吸入制剂,发展很快,本文概述了其中AERx胰岛素糖尿病治疗系统,Exubera胰岛素释药系统,Aerodose胰岛素吸入剂,AIR肺部释药系统,临床研究成效是好的,若长期应用的安全性和有效性得到确认,今后胰岛素肺部吸入代替注射的前程是乐观的。
Insulin is still the basic drug for the treatment of type 1 and type 2 diabetes. However, due to the fact that insulin is mainly administered by frequent injections, it brings many inconveniences and pains to the patients. Related scholars have done a lot of research to solve this problem. With the development of insulin pulmonary inhalation devices and dosage forms, clinical studies have found that systemic administration of insulin via the lung reduces multiple injections of type 1 diabetes and makes insulin treatment of type 2 diabetes more acceptable. In recent years, the rapid development of insulin pulmonary inhalation preparations, this article outlines the AERx insulin diabetes treatment system, Exubera insulin release system, Aerodose insulin inhaler, AIR lung release system, clinical research results are good, if long-term use The safety and effectiveness of this study have been confirmed. In the future, the future of insulin inhalation in lieu of injection is optimistic.